In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Reviving Europe's IPO Market: What VCs Need to Do

Executive Summary

Professor Christopher Evans, DSc, chairman of venture firm Merlin Biosciences, identified European public market investors' continued reluctance to support biotech IPOs as a significant threat to the sector's viability during a keynote presentation at the Financial Times Global Biotech conference in London in November. Yet there's a lot more VCs themselves can do to get the sector back on its feet, acknowledges Merlin's CEO Mark Clement, including putting more money into creating stronger companies from the outset, and simplifying approaches to, and support for, M&A.





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts